Frankincense

Within the SIRIAM Platform, Frankincense Essential Oil is classified as a Regional Signature Component.

Unlike the Structural & Dermal Support Core, Release Core and Integration Core ingredients, Frankincense is incorporated selectively into regional formulations according to their intended neurodermal objectives.

It is important to distinguish Frankincense Essential Oil from Boswellia serrata extract, which is included within the Release Core. Although both originate from Boswellia species, they represent fundamentally different pharmaceutical ingredients.

Boswellia serrata extract contributes standardized boswellic acids and serves as a universal Release Core botanical.

Frankincense Essential Oil contains volatile terpenes and sesquiterpenes that provide a distinct phytochemical profile and therefore functions as a Regional Signature Component.

Within the SIRIAM Platform, Frankincense contributes to the biological individuality of selected regional formulations while preserving the common platform architecture.

Frankincense is the aromatic oleo-gum resin obtained primarily from Boswellia carterii, Boswellia sacra, Boswellia frereana and related Boswellia species.

Unlike Boswellia resin extracts standardized for boswellic acids, the essential oil contains predominantly volatile compounds, including:

α-pinene

limonene

β-pinene

sabinene

incensole

incensole acetate

other monoterpenes and sesquiterpenes

Importantly, boswellic acids are largely absent from the distilled essential oil, meaning that the biological mechanisms differ substantially from those described for Boswellia resin extracts.

Experimental investigations have demonstrated several biological activities, including:

antioxidant effects;

modulation of inflammatory signalling;

antimicrobial activity;

influence on cytokine production;

effects on keratinocyte physiology;

experimental neuroprotective activity;

modulation of transient receptor potential (TRP) channels;

experimental influence on neuronal signalling pathways.

Particular scientific interest has focused on incensole acetate, which has demonstrated interactions with TRPV3 ion channels in experimental models. These findings suggest potential effects on cutaneous sensory physiology and neuronal regulation, although translation to human topical application remains uncertain.

Human clinical evidence for Frankincense Essential Oil is considerably more limited than for Boswellia resin extracts.

Clinical studies have investigated topical preparations in relation to:

skin ageing;

scar appearance;

skin hydration;

cutaneous topical dermatology.

Most studies are small and heterogeneous, preventing firm conclusions.

Current scientific evidence evaluates Frankincense Essential Oil as an isolated botanical ingredient within conventional topical preparations.

No published studies currently investigate its incorporation within a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform. Consequently, its inclusion reflects biological plausibility together with the architectural philosophy of the platform rather than established evidence for this specific pharmaceutical application.

Within the SIRIAM Platform, Frankincense functions as a Regional Signature Component.

Its role is to contribute to the phytochemical identity of selected regional formulations while remaining distinct from the Boswellia serrata Release Core ingredient.

Future optimisation may refine botanical species selection, concentration and incorporation methodology according to pharmaceutical development.